Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Conditions
- Myeloid Malignancies
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT04778410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- Drug: DS-1594bDrug: AzacitidineDrug: CyclophosphamideDrug: PosaconazoleDrug: VenetoclaxDrug: CytarabineDrug: VoriconazoleDrug: DexamethasoneBiological: FilgrastimDrug: LeucovorinDrug: MesnaDrug: MethotrexateDrug: PrednisoneBiological: RituximabDrug: Vincristine
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
- Conditions
- Age More 60yrLeukemia, Myeloid, AcuteDe Novo
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 84
- Registration Number
- NCT04687761
- Locations
- 🇪🇸
Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Spain
🇪🇸Hospital Clínic, Barcelona, Spain
🇪🇸Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
- Conditions
- LeukemiaGraft-versus-host-disease
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Yi Luo
- Target Recruit Count
- 46
- Registration Number
- NCT04688021
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Drug: IdarubicinDrug: Ara-CDrug: G-CSFProcedure: Allogeneic matched or unrelated donor transplant.Procedure: Autologous peripheral blood stem cell transplantProcedure: Measurable residual disease
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-06-27
- Target Recruit Count
- 1034
- Registration Number
- NCT04687098
- Locations
- 🇪🇸
ICO Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Universitari Son Espases, Palma de Mallorca, Mallorca, Spain
🇪🇸Hospital Universitari Son Llatzer, Palma de Mallorca, Mallorca, Spain
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateProcedure: Bone Marrow BiopsyDrug: CytarabineDrug: DaunorubicinProcedure: ElectrocardiographyDrug: Pemigatinib
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT04659616
- Locations
- 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Drug: AcalabrutinibDrug: BortezomibDrug: CyclophosphamideDrug: CytarabineDrug: Doxorubicin HydrochlorideDrug: PrednisoneBiological: RituximabBiological: Rituximab and Hyaluronidase Human
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 45
- Registration Number
- NCT04626791
- Locations
- 🇺🇸
Ochsner NCI Community Oncology Research Program, New Orleans, Louisiana, United States
🇺🇸Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 160
- Registration Number
- NCT04547049
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
🇨🇳The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Down SyndromeRecurrent B Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionRadiation: 3-Dimensional Conformal Radiation TherapyBiological: BlinatumomabProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CytarabineDrug: DexamethasoneDrug: Calaspargase PegolDrug: Hydrocortisone Sodium SuccinateProcedure: Lumbar PunctureDrug: MethotrexateBiological: NivolumabDrug: MercaptopurineDrug: PegaspargaseDrug: PegcrisantaspaseDrug: Vincristine Sulfate
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 300
- Registration Number
- NCT04546399
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyBiological: BlinatumomabDrug: DasatinibDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideProcedure: Multigated Acquisition ScanDrug: Ponatinib HydrochlorideProcedure: EchocardiographyProcedure: ElectrocardiographyDrug: PrednisoneProcedure: Lumbar PunctureDrug: MethotrexateDrug: MesnaDrug: Vincristine Sulfate
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 348
- Registration Number
- NCT04530565
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.